Hauptseite > Publikationsdatenbank > An orally available Ca v 2.2 calcium channel inhibitor for the treatment of neuropathic pain > print

001     1023080
005     20250204113805.0
024 7 _ |a 10.1111/bph.16309
|2 doi
024 7 _ |a 0007-1188
|2 ISSN
024 7 _ |a 0366-0826
|2 ISSN
024 7 _ |a 1476-5381
|2 ISSN
024 7 _ |a 2056-8177
|2 ISSN
024 7 _ |a 10.34734/FZJ-2024-01653
|2 datacite_doi
024 7 _ |a 38157867
|2 pmid
024 7 _ |a WOS:001158587800001
|2 WOS
037 _ _ |a FZJ-2024-01653
082 _ _ |a 610
100 1 _ |a Kutzsche, Janine
|0 P:(DE-Juel1)159137
|b 0
245 _ _ |a An orally available Ca v 2.2 calcium channel inhibitor for the treatment of neuropathic pain
260 _ _ |a Malden, MA
|c 2024
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1738246180_31341
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a AbstractBackground and Purpose:Neuropathic pain affects up to 10% of the global popula-tion and is caused by an injury or a disease affecting the somatosensory, peripheral,or central nervous system. NP is characterized by chronic, severe and opioid-resistantproperties. Therefore, its clinical management remains very challenging. The N-typevoltage-gated calcium channel, Cav2.2, is a validated target for therapeutic interven-tion in chronic and neuropathic pain. The conotoxin ziconotide (Prialt®) is an FDA-approved drug that blocks Cav2.2 channel but needs to be administered intrathecally.Thus, although being principally efficient, the required application route is very muchin disfavour.Experimental Approach and Key Results:Here, we describe an orally available drugcandidate, RD2, which competes with ziconotide binding to Cav2.2 at nanomolarconcentrations and inhibits Cav2.2 almost completely reversible. Other voltage-gatedcalcium channel subtypes, like Cav1.2 and Cav3.2, were affected by RD2 only at con-centrations higher than 10μM. Data from sciatic inflammatory neuritis rat modeldemonstrated thein vivoproof of concept, as low-dose RD2 (5 mgkg-1) administeredorally alleviated neuropathic pain compared with vehicle controls. High-dose RD2(50 mgkg-1) was necessary to reduce pain sensation in acute thermal responseassessed by the tail flick test.Conclusions and Implications:Taken together, these results demonstrate that RD2has antiallodynic properties. RD2 is orally available, which is the most convenientapplication form for patients and caregivers. The surprising and novel result fromstandard receptor screens opens the room for further optimization into new promis-ing drug candidates, which address an unmet medical need.
536 _ _ |a 5244 - Information Processing in Neuronal Networks (POF4-524)
|0 G:(DE-HGF)POF4-5244
|c POF4-524
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Guzman, Gustavo A.
|0 P:(DE-Juel1)165956
|b 1
700 1 _ |a Willuweit, Antje
|0 P:(DE-Juel1)144347
|b 2
700 1 _ |a Kletke, Olaf
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Wollert, Esther
|0 P:(DE-Juel1)180939
|b 4
700 1 _ |a Gering, Ian
|0 P:(DE-Juel1)171922
|b 5
700 1 _ |a Jürgens, Dagmar
|0 P:(DE-Juel1)144626
|b 6
700 1 _ |a Breitkreutz, Jörg
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Stark, Holger
|0 0000-0003-3336-1710
|b 8
700 1 _ |a Beck-Sickinger, Annette G.
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Klöcker, Nikolaj
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Hidalgo, Patricia
|0 P:(DE-Juel1)151357
|b 11
700 1 _ |a Willbold, Dieter
|0 P:(DE-Juel1)132029
|b 12
|e Corresponding author
773 _ _ |a 10.1111/bph.16309
|g p. bph.16309
|0 PERI:(DE-600)2029728-2
|n 12
|p 1734-1756
|t British journal of pharmacology
|v 181
|y 2024
|x 0007-1188
856 4 _ |u https://juser.fz-juelich.de/record/1023080/files/British%20J%20Pharmacology%20-%202023%20-%20Kutzsche%20-%20An%20orally%20available%20Cav2%202%20calcium%20channel%20inhibitor%20for%20the%20treatment%20of.pdf
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/1023080/files/British%20J%20Pharmacology%20-%202023%20-%20Kutzsche%20-%20An%20orally%20available%20Cav2%202%20calcium%20channel%20inhibitor%20for%20the%20treatment%20of.gif?subformat=icon
|x icon
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/1023080/files/British%20J%20Pharmacology%20-%202023%20-%20Kutzsche%20-%20An%20orally%20available%20Cav2%202%20calcium%20channel%20inhibitor%20for%20the%20treatment%20of.jpg?subformat=icon-1440
|x icon-1440
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/1023080/files/British%20J%20Pharmacology%20-%202023%20-%20Kutzsche%20-%20An%20orally%20available%20Cav2%202%20calcium%20channel%20inhibitor%20for%20the%20treatment%20of.jpg?subformat=icon-180
|x icon-180
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/1023080/files/British%20J%20Pharmacology%20-%202023%20-%20Kutzsche%20-%20An%20orally%20available%20Cav2%202%20calcium%20channel%20inhibitor%20for%20the%20treatment%20of.jpg?subformat=icon-640
|x icon-640
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:1023080
|p openaire
|p open_access
|p OpenAPC_DEAL
|p driver
|p VDB
|p openCost
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)159137
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)165956
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)144347
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-Juel1)180939
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)171922
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)144626
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 11
|6 P:(DE-Juel1)151357
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 12
|6 P:(DE-Juel1)132029
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-524
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Molecular and Cellular Information Processing
|9 G:(DE-HGF)POF4-5244
|x 0
914 1 _ |y 2024
915 p c |a APC keys set
|0 PC:(DE-HGF)0000
|2 APC
915 p c |a DEAL: Wiley 2019
|0 PC:(DE-HGF)0120
|2 APC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-22
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2023-08-22
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-22
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-31
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BRIT J PHARMACOL : 2022
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-31
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-31
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BRIT J PHARMACOL : 2022
|d 2024-12-31
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)IBI-7-20200312
|k IBI-7
|l Strukturbiochemie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)IBI-7-20200312
980 _ _ |a APC
980 _ _ |a UNRESTRICTED
980 1 _ |a APC
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21